Medidata Adds Video eConsent
Medidata, a Dassault Systèmes company, announced the addition of myMedidata eConsent, which enables video visits with patients and study staff. With video eConsent, trial participants can engage in remote, face-to-face, live conversation between patients and clinical trial site staff during the informed consent process. This expansion of the company’s telemedicine/video visit capability is the most recent addition to the myMedidata portal designed to be a single patient platform for all patient-centered technology.
The benefits of enabling video interaction during eConsent include:
- Enhanced patient experience by allowing patients to engage with their clinical research team prior to consenting
- Improved consent tracking management, which reduces informed consent errors and eases the administrative burden for sites and study teams
- Accessibility through the myMedidata patient portal so that patients can virtually access all of their trial needs in one location with one login.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
